Ergomed logo

ERGO - Ergomed News Story

615p 30.0  5.1%

Last Trade - 4:29pm

Sector
Healthcare
Size
Small Cap
Market Cap £283.2m
Enterprise Value £274.4m
Revenue £68.3m
Position in Universe 671st / 1819

Ergomed plc - Notice of AGM and Annual Report and Board Changes

Fri 15th May, 2020 7:00am
RNS Number : 9855M
Ergomed plc
15 May 2020
 

 PRESS RELEASE

 

 

Notice of AGM and Annual Report and Board Changes

 

 

Guildford, UK - 15 May 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that its Annual General Meeting ("AGM") will be held at the Company's registered offices at 1 Occam Court, Surrey Research Park, Guildford, GU2 7HJ at 9:30 a.m. on Wednesday, 10 June 2020. In light of the UK government's current COVID-19 measures, the AGM will be run as a closed meeting and shareholders will not be able to attend in person.

 

A letter explaining the AGM arrangements, together with Ergomed's Annual Report and Accounts for the year ended 31 December 2019, Notice of AGM and Form of Proxy will be available on the Company's website at www.ergomedplc.com and are being mailed to its shareholders today.

 

In conjunction with the upcoming AGM, Ergomed today announces that Dr Jim Esinhart will not be standing for re-election and will step down from the Board with immediate effect. The Company also announces that Rolf Soderstrom, a Non-Executive Director of the Company and Chairman of the Audit and Risk Committee, has assumed the additional role of Senior Independent Director.

 

Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: "On behalf of the Board, I would like to thank Jim for his contribution to Ergomed. We have been fortunate to benefit from his experience and knowledge of the global CRO industry, as we look to become a leading global provider of specialist services to the pharmaceutical industry. We respect his decision to step down in these unprecedented times and want to wish him well in the future. In addition, I am delighted that Rolf has assumed the additional role of Senior Independent Director and look forward to his continued significant contribution to the Board."

 

Dr Jim Esinhart commented: "I am pleased to have been part of this transformational year for Ergomed. I will continue to follow the Company with interest as it continues to develop as a specialist in the pharma services sector."

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

ergomed@consilium-comms.com

Matthew Neal / Olivia Manser




 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCAIMBTMTJBTMM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.